Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient

Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2016-05, Vol.95, p.35-38
Hauptverfasser:	Doesch, Janine, Debus, Dirk, Meyer, Christian, Papadopoulos, Thomas, Schultz, Erwin S, Ficker, Joachim H, Brueckl, Wolfgang M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - therapeutic use Afatinib Aged Female Hematology, Oncology and Palliative Medicine Humans Lung Neoplasms - complications Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Lung Neoplasms - genetics Mutation NSCLC Protein Kinase Inhibitors - adverse effects Pulmonary/Respiratory Quinazolines - adverse effects Receptor, Epidermal Growth Factor - genetics SJS Skin - pathology Stevens-Johnson Syndrome - diagnosis Stevens-Johnson Syndrome - drug therapy Stevens-Johnson Syndrome - etiology TKI Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Highlights • Afatinib is a tyrosine kinase inhibitor for first-line therapy in advanced non-small cell lung cancer. • Stevens-Johnson syndrome related to EGFR directed tyrosin kinase inhibitors as a rare adverse event. • first case report of SJS during afatinib treatment
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2016.02.015